Capillary Bed Bioreactor: Improved Estimation Of Dermal Bioavailability

从历史上看，动物试验被用来支持化妆品成分的风险评估。然而，近年来，为支持新化妆品的风险评估而进行的动物试验水平不断降低，并朝着对人类毒理学的机制理解（包括基于暴露的风险评估）的方向发展。因此，有必要开发用于预测新化学品安全性的非动物模型，以生成数据，从而提高对体内情景预测的信心。联合利华用于评估皮肤生物利用度的模型利用了扩散细胞中的皮肤（来自选择性整容手术程序），并且随着时间的推移监测测试项目通过皮肤的渗透。虽然这已被证明是一个适当的模型，但对通过真皮毛细血管清除化学物质知之甚少。提出的毛细管床生物反应器（CBB）通过提供中空纤维膜形式的假血管床，更好地复制了皮肤的体内环境及其血液供应。

Historically, animal testing has been used to support risk assessment related to cosmetic ingredients. However, in recent years, there has been a continuous drive to reduce the level of animal testing undertaken to support risk assessments for new cosmetic products, and a move towards a mechanistic understanding of human toxicology (incorporating exposure-based risk assessment). Consequently, the development of non-animal models for predicting the safety of new chemicals is necessary to generate data leading to increased confidence in predictions of in vivo scenarios. The model used by Unilever to assess dermal bioavailability utilises skin (from elective cosmetic surgery procedures) in diffusion cells, and the permeation of a test item through the skin is monitored over time. While this has proved to be an adequate model, little is known regarding chemical clearance via dermal capillaries. The proposed capillary bed bioreactor (CBB) better replicates the in vivo environment of the skin and its blood supply by providing a bed of pseudovascularisation in the form of hollow fibre membranes.